Key Points
- GSK insider Jonathan Symonds purchased 1,500 shares at GBX 1,881 each, for a total investment of £28,215.
- GSK shares opened at GBX 1,906, with a market capitalization of approximately £76.37 billion. The company reported quarterly EPS of GBX 10.80, a 14.52% net margin, and a 28.35% return on equity.
- Analysts have an overall “Hold” rating on GSK, with a consensus price target of GBX 2,064.38; individual targets range from GBX 1,975 to GBX 2,500.
GSK plc (LON:GSK - Get Free Report) insider Jonathan Symonds acquired 1,500 shares of the stock in a transaction on Friday, September 18th. The stock was bought at an average cost of GBX 1,881 per share, with a total value of £28,215.
GSK Price Performance
Shares of GSK stock opened at GBX 1,906 on Wednesday. The company has a market capitalization of £76.37 billion, a P/E ratio of 16.18, a P/E/G ratio of 1.24 and a beta of 0.29. The company's 50-day simple moving average is GBX 1,889.93 and its two-hundred day simple moving average is GBX 1,951.92. GSK plc has a one year low of GBX 1,455 and a one year high of GBX 2,282. The company has a debt-to-equity ratio of 103.36, a current ratio of 0.82 and a quick ratio of 0.73.
GSK (LON:GSK - Get Free Report) last posted its quarterly earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. As a group, equities analysts anticipate that GSK plc will post 175.980975 EPS for the current year.
Wall Street Analyst Weigh In
A number of equities research analysts have weighed in on GSK shares. Berenberg Bank lifted their target price on GSK from GBX 2,000 to GBX 2,200 and gave the company a "hold" rating in a research report on Tuesday, September 15th. Jefferies Financial Group restated a "buy" rating and issued a GBX 2,500 price objective on shares of GSK in a report on Wednesday, July 29th. Royal Bank Of Canada reaffirmed a "sector perform" rating and issued a GBX 1,975 price objective on shares of GSK in a research note on Tuesday, September 8th. Finally, Deutsche Bank Aktiengesellschaft reissued a "hold" rating and set a GBX 2,000 target price on shares of GSK in a research report on Tuesday, September 15th. Two equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of GBX 2,064.38.
Get Our Latest Stock Analysis on GSK
GSK Company Profile
(
Get Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
